Harrow closes acquisition of TYRVAYA from Viatris

• Harrow closed its acquisition of the dry eye nasal spray TYRVAYA from Viatris in an agreement valued at up to $100 million.
• The transaction includes an upfront cash payment of $30 million with up to $70 million in potential sales milestones.
• The company stated that approximately 40 Viatris personnel will join the organization during the fourth quarter of 2026.

Harrow (NASDAQ:HROW) closed the acquisition of TYRVAYA from Viatris to expand its commercial ophthalmic portfolio with an approved dry eye treatment.

The transaction secures worldwide commercial rights except for Japan, where Viatris retained commercialization rights and agreed to pay Harrow royalties on future net sales.

Harrow funded the initial $30 million payment using cash on hand, with potential milestone payments bringing total consideration to up to $100 million.

TYRVAYA is currently approved in the United States, China, and Taiwan, with additional marketing applications pending across global markets.

The company stated that approximately 40 Viatris personnel are expected to join during the fourth quarter of 2026 to support commercial integration.

Harrow expects the newly acquired nasal spray to contribute more than $30 million in revenue during the 2027 fiscal year.